| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| calcitonin salmon | Injection, solution | 100 IU/mL | Anticipated | Available | Unexpected increase in consumer demand | 23/01/2026 |
| lamotrigine | Tablet, chewable | 25 mg | Anticipated | Available | Manufacturing | 23/01/2026 |
| lamotrigine | Tablet, chewable | 200 mg | Anticipated | Available | Manufacturing | 23/01/2026 |
| cyproterone acetate | Tablet, uncoated | 50 mg | Resolved | Available | Manufacturing | 23/01/2026 |
| aripiprazole | Tablet, uncoated | 10 mg | Current | Limited Availability | Manufacturing | 23/01/2026 |
| mirtazapine | Tablet, film coated | 15 mg | Current | Limited Availability | Manufacturing | 23/01/2026 |
| quetiapine fumarate | Tablet, modified release | 172.695 mg | Anticipated | Available | Manufacturing | 23/01/2026 |
| elotuzumab | Injection, powder for | 340 mg | Anticipated | Available | Manufacturing | 23/01/2026 |
| trientine dihydrochloride | Capsule | 250 mg | Discontinued | Reduction in supply until supply is exhausted | Manufacturing | 23/01/2026 |
| lamotrigine | Tablet, chewable | 25 mg | Anticipated | Available | Manufacturing | 23/01/2026 |
| lamotrigine | Tablet, chewable | 200 mg | Current | Unavailable | Manufacturing | 23/01/2026 |
| rosuvastatin calcium | Tablet, film coated | 20.84 mg | Anticipated | Available | Manufacturing | 23/01/2026 |
| tirzepatide | Injection, solution | 5 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 23/01/2026 |
| tirzepatide | Injection, solution | 7.5 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 23/01/2026 |
| tirzepatide | Injection, solution | 12.5 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 23/01/2026 |
| tirzepatide | Injection, solution | 10 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 23/01/2026 |
| tirzepatide | Injection, solution | 15 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 23/01/2026 |
| tirzepatide | Injection, solution | 2.5 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 23/01/2026 |
| clindamycin phosphate | Cream | 22.8 mg/g | Anticipated | Available | Unexpected increase in consumer demand | 23/01/2026 |
| gliclazide | Tablet, uncoated | 80 mg | Anticipated | Available | Manufacturing | 23/01/2026 |
| methylphenidate hydrochloride | Capsule, modified release | 20 mg | Resolved | Available | Manufacturing | 23/01/2026 |
| digoxin | Injection, solution | .25 mg/mL | Resolved | Available | Manufacturing | 22/01/2026 |
| codeine phosphate hemihydrate | Oral Liquid, solution | 5 mg/mL | Current | Unavailable | Manufacturing | 22/01/2026 |
| lidocaine | Spray, solution | 100 mg/mL | Anticipated | Available | Manufacturing | 22/01/2026 |
| ciprofloxacin hydrochloride | Tablet, film coated | 832.5 mg | Current | Unavailable | Manufacturing | 22/01/2026 |
| olanzapine pamoate monohydrate | Injection, powder for | 690 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 22/01/2026 |
| nortriptyline | Tablet, film coated | 10 mg | Current | Limited Availability | Manufacturing | 22/01/2026 |
| aripiprazole | Tablet, uncoated | 10 mg | Resolved | Available | Manufacturing | 22/01/2026 |
| galantamine hydrobromide | Capsule, modified release | 20.512 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 22/01/2026 |
| pramipexole dihydrochloride monohydrate | Tablet | 1 mg | Resolved | Available | Manufacturing | 22/01/2026 |
| ondansetron hydrochloride dihydrate | Tablet, film coated | 9.972 mg | Resolved | Available | Manufacturing | 22/01/2026 |
| metronidazole | Tablet, uncoated | 400 mg | Current | Unavailable | Manufacturing | 22/01/2026 |
| mirtazapine | Tablet, orally disintegrating | 15 mg | Anticipated | Available | Manufacturing | 22/01/2026 |
| montelukast sodium | Tablet, chewable | 4.16 mg | Resolved | Available | Manufacturing | 22/01/2026 |
| montelukast sodium | Tablet | 10.4 mg | Anticipated | Available | Commercial Changes / Commercial viability | 22/01/2026 |
| quetiapine fumarate | Tablet, modified release | 172.695 mg | Current | Limited Availability | Manufacturing | 22/01/2026 |
| candesartan cilexetil~hydrochlorothiazide | Tablet, uncoated | 16 mg~12.5 mg | Anticipated | Available | Manufacturing | 22/01/2026 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Unavailable | Unexpected increase in consumer demand | 22/01/2026 |
| codeine phosphate hemihydrate | Oral Liquid | 5 mg/mL | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 22/01/2026 |
| hydrochlorothiazide~olmesartan medoxomil | Tablet | 12.5 mg~40 mg | Current | Unavailable | Manufacturing | 22/01/2026 |
| ondansetron hydrochloride dihydrate | Tablet, film coated | 9.972 mg | Resolved | Available | Manufacturing | 22/01/2026 |
| amlodipine besilate~olmesartan medoxomil | Tablet, film coated | 6.935 mg~20 mg | Current | Limited Availability | Manufacturing | 22/01/2026 |
| amlodipine besilate~olmesartan medoxomil | Tablet, film coated | 6.935 mg~40 mg | Current | Limited Availability | Manufacturing | 22/01/2026 |
| lacosamide | Tablet, film coated | 50 mg | Anticipated | Available | Manufacturing | 22/01/2026 |
| doxepin hydrochloride | Capsule, hard | 11.3 mg | Current | Unavailable | Manufacturing | 22/01/2026 |
| aprepitant | Capsule, hard | 165 mg | Anticipated | Available | Manufacturing | 22/01/2026 |
| gliclazide | Tablet, uncoated | 80 mg | Anticipated | Available | Manufacturing | 22/01/2026 |
| nitrofurantoin | Capsule, hard | 50 mg | Anticipated | Available | Unexpected increase in consumer demand | 22/01/2026 |
| nitrofurantoin | Capsule, hard | 100 mg | Current | Limited Availability | Unexpected increase in consumer demand | 22/01/2026 |
| nitrofurantoin | Capsule, hard | 100 mg | Current | Unavailable | Unexpected increase in consumer demand | 22/01/2026 |
| atracurium besilate | Injection, solution | 10 mg/mL | Resolved | Available | Manufacturing | 22/01/2026 |
| olanzapine | Tablet, film coated | 5 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 22/01/2026 |
| doxepin hydrochloride | Capsule, hard | 28.25 mg | Current | Unavailable | Manufacturing | 22/01/2026 |
| naratriptan hydrochloride | Tablet, film coated | 2.78 mg | Current | Unavailable | Manufacturing | 22/01/2026 |
| ziprasidone hydrochloride monohydrate | Capsule, hard | 22.65 mg | Anticipated | Available | Manufacturing | 22/01/2026 |
| desferrioxamine mesilate | Injection, powder for | 2 g | Current | Limited Availability | Manufacturing | 22/01/2026 |
| ciprofloxacin hydrochloride | Tablet, film coated | 873.32 mg | Resolved | Available | Manufacturing | 22/01/2026 |
| ciprofloxacin hydrochloride | Tablet, film coated | 582.21 mg | Current | Limited Availability | Manufacturing | 22/01/2026 |
| parecoxib sodium | Injection, powder for | 42.36 mg | Anticipated | Available | Manufacturing | 22/01/2026 |
| lamotrigine | Tablet, dispersible | 200 mg | Current | Unavailable | Manufacturing | 22/01/2026 |
| Coxiella burnetii | Injection | 50 microgram/mL | Current | Limited Availability | Manufacturing | 21/01/2026 |
| lidocaine hydrochloride | Gel | 20 mg/g | Anticipated | Available | Manufacturing | 21/01/2026 |
| ibuprofen~codeine phosphate hemihydrate | Tablet, film coated | 200 mg~12.8 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 21/01/2026 |
| Somatropin | Injection, powder for | 5 mg/mL | Anticipated | Available | Unexpected increase in consumer demand | 21/01/2026 |
| phenylephrine hydrochloride~prednisolone acetate | Eye Drops, suspension | 1.2 mg/mL~10 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 21/01/2026 |
| aprepitant | Capsule | 165 mg | Anticipated | Available | Manufacturing | 21/01/2026 |
| oseltamivir phosphate | Capsule, hard | 98.5 mg | Current | Unavailable | Unexpected increase in consumer demand | 21/01/2026 |
| sacubitril~valsartan | Tablet, film coated | 48.6 mg~51.4 mg | Current | Unavailable | Manufacturing | 21/01/2026 |
| valsartan~sacubitril | Tablet, film coated | 25.7 mg~24.3 mg | Current | Unavailable | Manufacturing | 21/01/2026 |
| valsartan~sacubitril | Tablet, film coated | 102.8 mg~97.2 mg | Current | Unavailable | Manufacturing | 21/01/2026 |
| flunitrazepam | Tablet, film coated | 1 mg | Current | Unavailable | Manufacturing | 21/01/2026 |
| galantamine hydrobromide~galantamine | Capsule, modified release | 10.25 mg~8 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 21/01/2026 |
| galantamine~galantamine hydrobromide | Capsule, modified release | 24 mg~30.76 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 21/01/2026 |
| lamotrigine | Tablet, chewable | 50 mg | Resolved | Available | Manufacturing | 20/01/2026 |
| tranexamic acid | Injection, solution | 1000 mg | Discontinued | Unavailable | Manufacturing | 20/01/2026 |
| riluzole | Tablet, film coated | 50 mg | Current | Unavailable | Manufacturing | 20/01/2026 |
| atorvastatin calcium trihydrate | Tablet, film coated | 21.69 mg | Current | Unavailable | Manufacturing | 20/01/2026 |
| pramipexole dihydrochloride monohydrate | Tablet | .25 mg | Current | Unavailable | Unexpected increase in consumer demand | 20/01/2026 |
| metformin hydrochloride | Tablet, modified release | 1000 mg | Resolved | Available | Manufacturing | 20/01/2026 |
| rosuvastatin calcium | Tablet, film coated | 10.42 mg | Current | Unavailable | Manufacturing | 20/01/2026 |
| bimatoprost | Eye Drops | .3 mg/mL | Current | Unavailable | Manufacturing | 20/01/2026 |
| methylphenidate hydrochloride | Capsule, modified release | 60 mg | Current | Limited Availability | Manufacturing | 20/01/2026 |
| tadalafil | Tablet | 10 mg | Discontinued | Reduction in supply until supply is exhausted | Manufacturing | 20/01/2026 |
| temozolomide | Capsule, hard | 5 mg | Anticipated | Available | Manufacturing | 20/01/2026 |
| methylphenidate hydrochloride | Capsule, modified release | 40 mg | Current | Limited Availability | Manufacturing | 20/01/2026 |
| rifampicin | Oral Liquid | 20 mg/mL | Anticipated | Available | Unexpected increase in consumer demand | 19/01/2026 |
| lidocaine hydrochloride | Injection, concentrated | 100 mg/mL | Anticipated | Available | Manufacturing | 19/01/2026 |
| topiramate | Tablet, film coated | 25 mg | Resolved | Available | Manufacturing | 19/01/2026 |
| risperidone | Tablet | 1 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 19/01/2026 |
| calcium folinate hydrate | Tablet, uncoated | 18.6 mg | Resolved | Available | Unexpected increase in consumer demand | 19/01/2026 |
| levetiracetam | Tablet, film coated | 500 mg | Resolved | Available | Manufacturing | 19/01/2026 |
| pramipexole dihydrochloride monohydrate | Tablet | .125 mg | Current | Unavailable | Manufacturing | 19/01/2026 |
| sildenafil citrate | Tablet, film coated | 140.45 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 19/01/2026 |
| ondansetron hydrochloride dihydrate | Tablet, film coated | 4.986 mg | Resolved | Available | Manufacturing | 19/01/2026 |
| indapamide hemihydrate | Tablet, sugar coated | 2.5 mg | Current | Unavailable | Manufacturing | 19/01/2026 |
| montelukast sodium | Tablet, chewable | 4.16 mg | Current | Unavailable | Manufacturing | 19/01/2026 |
| ambrisentan | Tablet, film coated | 10 mg | Resolved | Available | Manufacturing | 19/01/2026 |
| moxonidine | Tablet, film coated | 400 microgram | Current | Limited Availability | Commercial Changes / Commercial viability | 19/01/2026 |
| moxonidine | Tablet, film coated | 200 microgram | Current | Unavailable | Commercial Changes / Commercial viability | 19/01/2026 |
| rasagiline mesilate | Tablet | 1.56 mg | Current | Unavailable | Manufacturing | 19/01/2026 |
| eplerenone | Tablet, film coated | 50 mg | Resolved | Available | Manufacturing | 19/01/2026 |
| eplerenone | Tablet, film coated | 25 mg | Resolved | Available | Manufacturing | 19/01/2026 |
| levothyroxine sodium | Tablet | .075 mg | Current | Limited Availability | Manufacturing | 19/01/2026 |
2026年1月26日